Editorial: Steroid hormone receptors and cell cycle in breast cancer

por Fabris, Victoria T., Spring, Laura, Helguero, Luisa A.
Publicado 2023

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

por Spring, Laura M., Zangardi, Mark L., Moy, Beverly, Bardia, Aditya
Publicado 2017

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer

por Brett, Jamie O., Spring, Laura M., Bardia, Aditya, Wander, Seth A.
Publicado 2021

Mechanisms of Resistance to Antibody–Drug Conjugates

por Abelman, Rachel Occhiogrosso, Wu, Bogang, Spring, Laura M., Ellisen, Leif W., Bardia, Aditya
Publicado 2023

Stevens-Johnson syndrome–like eruption from palbociclib in a patient with metastatic breast cancer

por Karagounis, Theodora, Vallurupalli, Mounica, Nathan, Neera, Nazarian, Rosalynn, Vedak, Priyanka, Spring, Laura, Chen, Steven T.
Publicado 2018

Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic

por Spring, Laura M., Specht, Michelle C., Jimenez, Rachel B., Isakoff, Steven J., Wang, Gary X., Ly, Amy, Shin, Jennifer A., Bardia, Aditya, Moy, Beverly
Publicado 2020

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer

por McLaughlin, Shannon, Nakajima, Erika, Bar, Yael, Hutchinson, Jennifer A., Shin, Jennifer, Moy, Beverly, Isakoff, Steven J., Bardia, Aditya, Kuter, Irene, Spring, Laura M.
Publicado 2023

A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry

por Smith, Barbara L., Nguyen, Anvy, Korotkin, Jenna E., Kelly, Bridget N., Specht, Michelle C., Spring, Laura M., Moy, Beverly, Isakoff, Steven J., Gadd, Michele A.
Publicado 2020

Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study)

por Isakoff, Steven J., Said, Maya R., Kwak, Agnes H., Glieberman, Eva, O’Rourke, Emily A., Stroiney, Amanda, Spring, Laura M., Moy, Beverly, Bardia, Aditya, Horick, Nora, Peppercorn, Jeffrey M.
Publicado 2023

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer

por Spring, Laura M., Clark, Shealagh L., Li, Tianyu, Goel, Shom, Tayob, Nabihah, Viscosi, Elene, Abraham, Elizabeth, Juric, Dejan, Isakoff, Steven J., Mayer, Erica, Moy, Beverly, Supko, Jeffrey G., Tolaney, Sara M., Bardia, Aditya
Publicado 2021

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

por Spring, Laura M., Han, Hyo, Liu, Minetta C., Hamilton, Erika, Irie, Hanna, Santa-Maria, Cesar A., Reeves, James, Pan, Peng, Shan, Ming, Tang, Yongqiang, Graham, Julie R., Hazard, Sebastien, Ellisen, Leif W., Isakoff, Steven J.
Publicado 2022

Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

por Spring, Laura M., Han, Hyo, Liu, Minetta C., Hamilton, Erika, Irie, Hanna, Santa-Maria, Cesar A., Reeves, James, Pan, Peng, Shan, Ming, Tang, Yongqiang, Graham, Julie R., Hazard, Sebastien, Ellisen, Leif W., Isakoff, Steven J.
Publicado 2022

Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series

por Brett, Jamie O, Ritterhouse, Lauren L, Newman, Erik T, Irwin, Kelly E, Dawson, Megan, Ryan, Lianne Y, Spring, Laura M, Rivera, Miguel N, Lennerz, Jochen K, Dias-Santagata, Dora, Ellisen, Leif W, Bardia, Aditya, Wander, Seth A
Publicado 2022

TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis

por Medford, Arielle J., Oshry, Lauren, Boyraz, Baris, Kiedrowski, Lesli, Menshikova, Sofia, Butusova, Anna, Dai, Charles S., Gogakos, Tasos, Keenan, Jennifer C., Occhiogrosso, Rachel H., Ryan, Phoebe, Lennerz, Jochen K., Spring, Laura M., Moy, Beverly, Ellisen, Leif W., Bardia, Aditya
Publicado 2023

Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses

por Koh, Siang-Boon, Dontchos, Brian N., Bossuyt, Veerle, Edmonds, Christine, Cristea, Simona, Melkonjan, Nsan, Mortensen, Lindsey, Ma, Annie, Beyerlin, Kassidy, Denault, Elyssa, Niehoff, Elizabeth, Hirz, Taghreed, Sykes, David B., Michor, Franziska, Specht, Michelle, Lehman, Constance, Ellisen, Leif W., Spring, Laura M.
Publicado 2021

Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy

por Griffiths, Jason I., Chen, Jinfeng, Cosgrove, Patrick A., O’Dea, Anne, Sharma, Priyanka, Ma, Cynthia, Trivedi, Meghna, Kalinsky, Kevin, Wisinski, Kari B., O’Regan, Ruth, Makhoul, Issam, Spring, Laura M., Bardia, Aditya, Adler, Frederick R., Cohen, Adam L., Chang, Jeffrey T., Khan, Qamar J., Bild, Andrea H.
Publicado 2021

Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer

por Medford, Arielle J., Dubash, Taronish D., Juric, Dejan, Spring, Laura, Niemierko, Andrzej, Vidula, Neelima, Peppercorn, Jeffrey, Isakoff, Steven, Reeves, Brittany A., LiCausi, Joseph A., Wesley, Benjamin, Malvarosa, Giuliana, Yuen, Megan, Wittner, Ben S., Lawrence, Michael S., Iafrate, A. John, Ellisen, Leif, Moy, Beverly, Toner, Mehmet, Maheswaran, Shyamala, Haber, Daniel A., Bardia, Aditya
Publicado 2019

Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer

por Denault, Elyssa, Nakajima, Erika, Naranbhai, Vivek, Hutchinson, Jennifer A., Mortensen, Lindsey, Neihoff, Elizabeth, Barabell, Caroline, Comander, Amy, Juric, Dejan, Kuter, Irene, Mulvey, Theresa, Peppercorn, Jeffrey, Rosenstock, Aron S., Shin, Jennifer, Vidula, Neelima, Wander, Seth A., Moy, Beverly, Ellisen, Leif W., Isakoff, Steven J., Iafrate, A. John, Gainor, Justin F., Bardia, Aditya, Spring, Laura M.
Publicado 2022

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer

por Waks, Adrienne G., Desai, Neelam V., Li, Tianyu, Poorvu, Philip D., Partridge, Ann H., Sinclair, Natalie, Spring, Laura M., Faggen, Meredith, Constantine, Michael, Metzger, Otto, Alberti, Jillian, Deane, Julia, Rosenberg, Shoshana M., Frank, Elizabeth, Tolaney, Sara M., Krop, Ian E., Tung, Nadine M., Tayob, Nabihah, King, Tari A., Mittendorf, Elizabeth A., Winer, Eric P.
Publicado 2022

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

por Keenan, Tanya E., Guerriero, Jennifer L., Barroso-Sousa, Romualdo, Li, Tianyu, O’Meara, Tess, Giobbie-Hurder, Anita, Tayob, Nabihah, Hu, Jiani, Severgnini, Mariano, Agudo, Judith, Vaz-Luis, Ines, Anderson, Leilani, Attaya, Victoria, Park, Jihye, Conway, Jake, He, Meng Xiao, Reardon, Brendan, Shannon, Erin, Wulf, Gerburg, Spring, Laura M., Jeselsohn, Rinath, Krop, Ian, Lin, Nancy U., Partridge, Ann, Winer, Eric P., Mittendorf, Elizabeth A., Liu, David, Van Allen, Eliezer M., Tolaney, Sara M.
Publicado 2021